Press Release Nov 09 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
The product is available in multiple strengths and was launched in partnership with Juno Pharmaceuticals Pty Ltd. Pomalidomide is used for treating Multiple Myeloma and Kaposi Sarcoma, with significant sales reported in the Australian market for the previous year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from NATCO Pharma
- Press Release Oct 21 2022
- Press Release Oct 04 2022
- Press Release Sep 24 2022
- Press Release Sep 19 2022
- Press Release Aug 17 2022
Later from NATCO Pharma
- Press Release Nov 12 2022
- Press Release Nov 16 2022
- Press Release Dec 05 2022
- Press Release Feb 04 2023
- Natco Pharma Limited Press Release Feb 13 2023
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma